Trial0

Clinical trial · NCT07165132 · RECRUITING · PHASE1

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Sponsor: RayzeBio, Inc.

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Interventions

  • RYZ401 · DRUG

    Ac-225

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion criteria:

* At least 18 years old at the time of signing the main study informed consent form (ICF).
* Histologically confirmed:

Dose Escalation (all cohorts): Grades 1-3 WD, metastatic or locally advanced and unresectable NET at any primary site, including, but not limited to, GI, pancreatic, lung, thyroid, breast, urogenital, and adrenal tumors.

* Dose Expansion Cohort A: Grades 1-3 WD, metastatic or locally advanced and unresectable GEP-NETs
* Dose Expansion Cohort B: metastatic or locally advanced and unresectable tumors known to frequently express SSTR, limited to the following indications:

  * WD NETs (Grades 1-3) from primary sites other than gastrointestinal and pancreatic (including, but not limited to, lung, thyroid, breast, urogenital, and adrenal tumors) Meningioma (Grades 1-3)

    * SSTR-positive disease, as assessed by SSTR-PET imaging
    * Adequate renal, hematologic and hepatic function

Exclusion criteria:

* Prior RPT, including Lu-177.
* Prior solid organ or bone marrow transplantation.
* Use of chronic systemic steroid therapy.
* Significant cardiovascular disease
* Resistant hypertension
* Uncontrolled diabetes
* Prior history of liver cirrhosis
* HIV, hepatitis B infection or known active hepatitis C virus infection.

Note: Additional criteria may apply and will be assessed by the study site

Sites (9)

  • Research Facility, Iowa City, Iowa · RECRUITING
  • Research Facility, Lexington, Kentucky · RECRUITING
  • Research Facility, St Louis, Missouri · RECRUITING
  • Research Facility, St Louis, Missouri · RECRUITING
  • Research Facility, Columbus, Ohio · RECRUITING
  • Research Facility, Nashville, Tennessee · RECRUITING
  • Research Facility, Salt Lake City, Utah · RECRUITING
  • Research Facility, Toronto, Ontario, Canada · RECRUITING
  • Research Facility, Montreal, Quebec, Canada · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-06-09.